Opendata, web and dolomites

POLYMMUNE SIGNED

Off-the-Shelf Polypeptide-based Immunotherapy for Advanced Melanoma Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 POLYMMUNE project word cloud

Explore the words cloud of the POLYMMUNE project. It provides you a very rough idea of what is the project "POLYMMUNE" about.

despite    medicine    erc    successes    shelf    business    viability    commercially    overcome    outcome    pharmaceutical    nanocarrier    benefit    immunotherapy    drugs    diseases    biotechnology    blood    action    coupling    reactions    broad    variety    will    mynano    treatments    clinical    modification    cheaper    immunotherapies    additionally    metastatic    globally    heavily    offers    patients    off    administered    intranasally    bypass    activated    commercial    132    proof    depending    therapeutics    immune    nanogel    neurodegenerative    grant    severe    bottle    diagnosed    attractive    effects    treatment    therapeutic    causing    minimising    ing    costly    brain    desired    activate    platform    polymeric    scalable    melanoma    envision    consolidator    interplay    drug    strategies    industrially    antigen    cancer    potentially    50    site    conjugate    invest    neck    medical    companies    nanoconjugates    polymmune    vaccine    conjugates    fold    types    dual    barrier   

Project "POLYMMUNE" data sheet

The following table provides information about the project.

Coordinator
FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE 

Organization address
address: CALLE EDUARDO PRIMO YUFERA 3
city: VALENCIA
postcode: 46012
website: http://www.cipf.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 149˙938 €
 EC max contribution 149˙938 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE ES (VALENCIA) coordinator 149˙938.00

Map

 Project objective

Despite various existing drug delivery methods, the key challenge remains: how to deliver drugs to the desired site of therapeutic action to achieve best treatment outcome, while minimising side effects? This is even more challenging in cancer immunotherapy as a complex interplay of immune reactions need to be activated. POLYMMUNE will evaluate the technical and commercial viability of our novel polymeric nanocarrier platform (developed during my ERC Consolidator grant MyNano) for targeted drug delivery of a wide variety of diseases and therapeutics. As proof of concept, we will focus on immunotherapy delivery for metastatic melanoma. Globally ~132,000 new melanoma cases will be diagnosed each year and despite recent successes, only 50% of the patients respond to novel immunotherapies that are costly, while causing severe side effects. Coupling a commercially available antigen against metastatic melanoma to our nanocarrier will activate a broad immune response, resulting in an effective cancer vaccine that potentially targets different melanoma types, enabling off-the-shelf production. This dual action will lead to increased clinical benefit, which will come with less side effects and will be 5-10-fold cheaper than current treatments. Additionally, our conjugate is industrially scalable and thus overcome a major bottle neck of current nanocarrier-based medicine. We envision our platform technology to be used as a method of choice for drug delivery in many medical applications, such as cancer immunotherapy and neurodegenerative diseases. These applications are within reach, as depending on the modification, our conjugates can e.g. bypass the blood brain barrier and potentially be administered intranasally (nanogel). Our platform offers a highly attractive business case, as biotechnology and pharmaceutical companies heavily invest in nanoconjugates due to the need for novel drug delivery strategies.

 Publications

year authors and title journal last update
List of publications.
2019 Liane I. F. Moura, Alessio Malfanti, Carina Peres, Ana I. Matos, Elise Guegain, Vanessa Sainz, Mire Zloh, María J. Vicent, Helena F. Florindo
Functionalized branched polymers: promising immunomodulatory tools for the treatment of cancer and immune disorders
published pages: , ISSN: 2051-6347, DOI: 10.1039/c9mh00628a
Materials Horizons Advanced article 2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POLYMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More